Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

Key Takeaway: Natera won the Best in Class award in Cancer, Screening & Early Detection at the 2026 HLTH Conference. The Digital Health Hub Foundation honored the company for its Signatera molecular residual disease test. The recognition highlights the test's impact on cancer care during the Las Vegas event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Natera recognized as Best in Class in cancer detection.
  • Signatera™ test positively impacts cancer care.
  • Recognition received at a prominent health conference.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the impact of Natera’s Signatera™ molecular residual disease (MRD) test on cancer care.The winners were announced live at the 2026 HLTH Conference in Las Vegas. This

Frequently Asked Questions

What award did Natera win?

Natera won the Best in Class award in cancer detection.

What is the Signatera™ test?

Signatera™ is a molecular residual disease test for cancer care.

Where was the award announced?

The award was announced at the 2026 HLTH Conference in Las Vegas.

Who presented the Digital Health & AI Awards?

The awards were presented by the Digital Health Hub Foundation.

Last updated: Nov 17, 2026